188 related articles for article (PubMed ID: 20044279)
1. Treatment with telmisartan attenuates graft arteriosclerosis in murine cardiac allografts.
Kosuge H; Ishihara T; Haraguchi G; Maejima Y; Okada H; Saiki H; Suzuki J; Isobe M
J Heart Lung Transplant; 2010 May; 29(5):562-7. PubMed ID: 20044279
[TBL] [Abstract][Full Text] [Related]
2. Pioglitazone prevents acute and chronic cardiac allograft rejection.
Kosuge H; Haraguchi G; Koga N; Maejima Y; Suzuki J; Isobe M
Circulation; 2006 Jun; 113(22):2613-22. PubMed ID: 16735678
[TBL] [Abstract][Full Text] [Related]
3. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.
Imayama I; Ichiki T; Inanaga K; Ohtsubo H; Fukuyama K; Ono H; Hashiguchi Y; Sunagawa K
Cardiovasc Res; 2006 Oct; 72(1):184-90. PubMed ID: 16938288
[TBL] [Abstract][Full Text] [Related]
4. Attenuation of graft arterial disease by manipulation of the LIGHT pathway.
Kosuge H; Suzuki J; Kakuta T; Haraguchi G; Koga N; Futamatsu H; Gotoh R; Inobe M; Isobe M; Uede T
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1409-15. PubMed ID: 15178556
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of tumor necrosis factor-alpha-induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator-activated receptor-gamma with nuclear factor kappaB and CCAAT/enhancer-binding protein-beta.
Tian Q; Miyazaki R; Ichiki T; Imayama I; Inanaga K; Ohtsubo H; Yano K; Takeda K; Sunagawa K
Hypertension; 2009 May; 53(5):798-804. PubMed ID: 19289654
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-16 deficiency suppresses the development of chronic rejection in murine cardiac transplantation model.
Kimura N; Itoh S; Nakae S; Axtell RC; Velotta JB; Bos EJ; Merk DR; Gong Y; Okamura H; Nagamine CM; Adachi H; Kornfeld H; Robbins RC; Fischbein MP
J Heart Lung Transplant; 2011 Dec; 30(12):1409-17. PubMed ID: 22055099
[TBL] [Abstract][Full Text] [Related]
7. Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice.
Iwanami J; Mogi M; Tsukuda K; Min LJ; Sakata A; Jing F; Iwai M; Horiuchi M
J Hypertens; 2010 Aug; 28(8):1730-7. PubMed ID: 20498620
[TBL] [Abstract][Full Text] [Related]
8. Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase.
Yuen CY; Wong WT; Tian XY; Wong SL; Lau CW; Yu J; Tomlinson B; Yao X; Huang Y
Cardiovasc Res; 2011 Apr; 90(1):122-9. PubMed ID: 21156825
[TBL] [Abstract][Full Text] [Related]
9. The angiotensin II type 1 receptor blocker candesartan attenuates graft vasculopathy.
Yamamoto T; Sata M; Fukuda D; Takamoto S
J Surg Res; 2006 May; 132(1):62-8. PubMed ID: 16140337
[TBL] [Abstract][Full Text] [Related]
10. Telmisartan inhibits vascular dysfunction and inflammation via activation of peroxisome proliferator-activated receptor-γ in subtotal nephrectomized rat.
Toba H; Tojo C; Wang J; Noda K; Kobara M; Nakata T
Eur J Pharmacol; 2012 Jun; 685(1-3):91-8. PubMed ID: 22314223
[TBL] [Abstract][Full Text] [Related]
11. Telmisartan, a dual ARB/partial PPAR-γ agonist, protects myocardium from ischaemic reperfusion injury in experimental diabetes.
Goyal SN; Bharti S; Bhatia J; Nag TC; Ray R; Arya DS
Diabetes Obes Metab; 2011 Jun; 13(6):533-41. PubMed ID: 21320264
[TBL] [Abstract][Full Text] [Related]
12. Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-gamma activation.
Yamamoto K; Ohishi M; Ho C; Kurtz TW; Rakugi H
Hypertension; 2009 Dec; 54(6):1353-9. PubMed ID: 19822796
[TBL] [Abstract][Full Text] [Related]
13. Telmisartan exerts antiatherosclerotic effects by activating peroxisome proliferator-activated receptor-γ in macrophages.
Matsumura T; Kinoshita H; Ishii N; Fukuda K; Motoshima H; Senokuchi T; Taketa K; Kawasaki S; Nishimaki-Mogami T; Kawada T; Nishikawa T; Araki E
Arterioscler Thromb Vasc Biol; 2011 Jun; 31(6):1268-75. PubMed ID: 21474824
[TBL] [Abstract][Full Text] [Related]
14. Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan.
Clemenz M; Frost N; Schupp M; Caron S; Foryst-Ludwig A; Böhm C; Hartge M; Gust R; Staels B; Unger T; Kintscher U
Diabetes; 2008 May; 57(5):1405-13. PubMed ID: 18184928
[TBL] [Abstract][Full Text] [Related]
15. PPARγ attenuates intimal hyperplasia by inhibiting TLR4-mediated inflammation in vascular smooth muscle cells.
Zhang LL; Gao CY; Fang CQ; Wang YJ; Gao D; Yao GE; Xiang J; Wang JZ; Li JC
Cardiovasc Res; 2011 Dec; 92(3):484-93. PubMed ID: 21880694
[TBL] [Abstract][Full Text] [Related]
16. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats.
Kobayashi N; Ohno T; Yoshida K; Fukushima H; Mamada Y; Nomura M; Hirata H; Machida Y; Shinoda M; Suzuki N; Matsuoka H
Am J Hypertens; 2008 May; 21(5):576-81. PubMed ID: 18437150
[TBL] [Abstract][Full Text] [Related]
17. Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change.
Ikejima H; Imanishi T; Tsujioka H; Kuroi A; Kobayashi K; Shiomi M; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
J Hypertens; 2008 May; 26(5):964-72. PubMed ID: 18398339
[TBL] [Abstract][Full Text] [Related]
18. Telmisartan modulates mitochondrial function in vascular smooth muscle cells.
Takeuchi K; Yamamoto K; Ohishi M; Takeshita H; Hongyo K; Kawai T; Takeda M; Kamide K; Kurtz TW; Rakugi H
Hypertens Res; 2013 May; 36(5):433-9. PubMed ID: 23254392
[TBL] [Abstract][Full Text] [Related]
19. Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor γ among clinically used angiotensin II receptor blockers: drug-target interaction analyses.
Kakuta H; Kurosaki E; Niimi T; Gato K; Kawasaki Y; Suwa A; Honbou K; Yamaguchi T; Okumura H; Sanagi M; Tomura Y; Orita M; Yonemoto T; Masuzaki H
J Pharmacol Exp Ther; 2014 Apr; 349(1):10-20. PubMed ID: 24424487
[TBL] [Abstract][Full Text] [Related]
20. Telmisartan protects against vascular dysfunction with peroxisome proliferator-activated receptor-γ activation in hypertensive 5/6 nephrectomized rats.
Toba H; Wang J; Ohigashi M; Kobara M; Nakata T
Pharmacology; 2013; 92(5-6):265-75. PubMed ID: 24281041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
